MINSK, 30 October (BelTA) – All volunteers taking part in human trials of Russia's coronavirus vaccine Sputnik V have received the first component of the vaccine, the press service of Russia's Ministry of Health told reporters, TASS informs.
During the double blind randomized placebo-controlled study of Russia's COVID-19 vaccine Sputnik V (Gam-COVID-Vac) on 29 October, Belarus finished giving the first component of the vaccine to volunteers (100 people received the shots). The second component was given to 11 volunteers.
All the volunteers are observed for 180 days after getting the first shots. Specialists assess the vaccine efficacy, potency and safety. “The single approach to the study design in the Russian Federation and Belarus will ensure the consistency of data received in the two countries. Based on that a decision will be made whether the vaccine will be registered in Belarus,” the press service added.
Belarus was the first country outside Russia to begin clinical trials of the Sputnik V vaccine after it was registered in Russia. The trials will take place in eight healthcare institutions in Belarus.